Emodin

Emodin: A Comprehensive Reference

1. Identity and Chemical Characterization

Chemical Names and Nomenclature

Emodin (6-methyl-1,3,8-trihydroxyanthraquinone) is a naturally occurring anthraquinone derivative found in roots and leaves of various plants, fungi, and lichens. The systematic IUPAC name is 1,3,8-trihydroxy-6-methylanthracene-9,10-dione, with the molecular formula C₁₅H₁₀O₅. Common synonyms include emodol, frangula emodin, rheum emodin, and 3-methyl-1,6,8-trihydroxyanthraquinone. The common name is derived from Rheum emodi, a taxonomic synonym of Rheum australe (Himalayan rhubarb).

Physical and Structural Properties

The molecular formula of emodin is C₁₅H₁₀O₅ with a molecular weight of 270.23. It is commonly encountered as an orange powder, with a melting point range of 256–257°C. Emodin possesses a tricyclic planar structure with multiple modification sites, including a hydroxyl group at position 3, an anthraquinone ring at positions 2 and 4, and a methyl group at position 6. Emodin contains multiple hydroxyl and carbonyl groups in its structure, which can chelate with metal ions in biological target enzymes to form relatively stable chelates, a property considered important for its wide biological activity. In nature, anthraquinone compounds such as emodin are found in the form of anthraquinone glycosides, most commonly with glucose or rhamnose as the sugar component. They are solid substances, usually in the form of orange crystals.

Classification

Emodin is a bioactive compound — a natural anthraquinone aglycone — present mainly in herbaceous species of the families Fabaceae, Polygonaceae, and Rhamnaceae, with a physiological role in protection against abiotic stress in vegetative tissues. The activity of anthraquinone compounds depends on their chemical structures and is related to the presence of hydroxyl groups at C-1 and C-8 in the aromatic ring, the nature of a substituent at C-3, and the number of sugar residues. Anthraquinone compounds occur either in oxidized (anthraquinones) or reduced form (anthrones, anthranols), and also as dimers (dianthrones).

2. Natural Sources

Principal Plant Sources

The highest and most consistently reported occurrence of emodin-related metabolites are found in species belonging to the families Polygonaceae and Fabaceae, which constitute the principal botanical sources. Within Polygonaceae, species of the genus Rheum represent the most prominent and pharmacopoeially recognized sources. Medicinal rhubarb species, including Rheum palmatum, R. officinale, and R. tanguticum, accumulate emodin predominantly in their rhizomes and roots. In these tissues, emodin is a characteristic anthraquinone marker and occurs alongside structurally related compounds such as rhein, chrysophanol, physcion, and aloe-emodin.

Emodin is particularly abundant in the roots of the Chinese rhubarb (Rheum palmatum), knotweed and knotgrass (Polygonum cuspidatum and Polygonum multiflorum) as well as Hawaii 'au'auko'i cassia seeds or coffee weed (Semen cassia). It is also produced by many species of fungi, including members of the genera Aspergillus, Pyrenochaeta, and Pestalotiopsis.

Rhubarb is mainly produced in the high-altitude mountainous areas of temperate and subtropical Asia, including but not limited to the northwest and southwest of China (Gansu province, Qinghai province, Sichuan province, and Tibet Autonomous Region).

Fungal Sources

Emodin is also found in roots and leaves of various fungi and lichens. The compound's biosynthesis proceeds through the polyketide pathway: emodin is synthesized by acetyl CoA carboxylase (ACC1), polyketide synthase (PKS), thioesterase (MβL-TE), and decarboxylase (DC) and other enzymes, starting from pyruvate.

Pharmacopoeial Status

The source plants Rheum palmatum (RP), Polygonum multiflorum (PM), and Polygonum cuspidatum (PC) are included in the Chinese Pharmacopoeia 2020, although their traditional functions differ: RP mainly has the effect of heat-clearing and diuresis-promoting, PM is mainly used to tonify the liver and kidneys, and PC mainly has the effect of removing dampness and reducing jaundice. Emodin is now also a commonly used clinical entity and is listed in the Chinese Pharmacopoeia.

3. Traditional and Historical Uses

Traditional Chinese Medicine

Emodin has been used for over 2,000 years in eastern Asia and is still present in various herbal preparations. Rhei Radix et Rhizoma, also known as rhubarb or Da Huang, has been widely used as a spice and as traditional herbal medicine for centuries, and is currently marketed in China as the principal herb in various prescriptions, such as Da-Huang-Zhe-Chong pills and Da-Huang-Qing-Wei pills.

Rhubarb was first recorded in Shen Nong Ben Cao Jing, the earliest systematic monograph concerning Traditional Chinese Medicine (TCM), and has been clinically practiced for over 2,000 years. In TCM, emodin-containing preparations are mainly used to treat sore throats, carbuncles, sores, blood stasis, and damp-heat jaundice.

Notable natural sources include the roots and rhizomes of rhubarb (Rheum palmatum), buckthorn (Rhamnus cathartica), and Japanese knotweed (Reynoutria japonica). These plants have been utilized for centuries in traditional medicine systems, such as Traditional Chinese Medicine, often for their purgative or laxative effects.

Laxative and Digestive Tradition

There is extensive exposure to emodin and other anthraquinones resulting from the use of herb-based stimulant laxatives. The content of free anthraquinones, including emodin, changes during the processing of P. multiflorum, with emodin content increasing after prolonged processing times. In traditional practice, the herbs were prepared in a variety of decoctions, water extractions, and powdered forms, and were administered orally for constipation, abdominal distension, and bowel cleansing.

Ayurvedic and Other Systems

Historically, emodin-containing plants have been used in traditional medicine systems such as Traditional Chinese Medicine and Ayurveda for their purported laxative, anti-inflammatory, and antimicrobial properties.

4. Key Constituents and Companion Compounds

Emodin does not exist alone in its source plants. In rhubarb-derived preparations, emodin occurs alongside structurally related compounds such as rhein, chrysophanol, physcion, and aloe-emodin, forming the chemical basis of the biological activities attributed to rhubarb-derived preparations. The absorption of emodin was found to be faster, and its effect more rapid, when used in combination with aloe-emodin, rhein, chrysophanol, or physcion.

5. Mechanisms of Action

Anti-Inflammatory Pathways

Emodin can regulate signal transduction pathways with various pharmacological properties. Anti-inflammatory activity mainly involves NLRP3, NF-κB, mTOR, Notch, and JAK1/STAT3 pathways; anti-tumor activity mainly involves PI3K/AKT, NF-κB, TRAF6, and EMT pathways; and antibacterial activity mainly involves NF-κB and PPARγ pathways.

The inflammatory signaling pathways inhibited by emodin mainly include the NF-κB signaling pathway and the MAPK signaling pathway, which lead to: prevention of fatty liver from progressing to non-alcoholic steatohepatitis (NASH) by reducing the release of inflammatory cytokines (IL-1β, IL-6, and TNF-α); improvement in renal function by inhibiting the expression of CREB and FN protein; and inhibition of related oncogenic protein expression. In a collagen-induced arthritic mouse model, emodin exhibited its anti-arthritis effects through inhibition of the NF-κB pathway and pro-inflammatory mediators.

Anticancer Mechanisms

Emodin exerts anti-tumor effects by modulating multiple hallmarks of cancer, including cell growth (suppression of proliferation, promotion of apoptosis, and altered cellular redox status), epithelial-mesenchymal transition (EMT), invasion and metastasis, and tumor angiogenesis. Multiple oncogenic signaling pathways and molecules modulated by emodin have been identified, including NF-κB, HER-2, HIF-1α, AKT/mTOR, STAT3, Wnt, p38/p53/Puma, and VEGFR-2.

These effects are mediated through the activation of the p38 MAPK/JNK1/2 signaling pathway, the upregulation of pro-apoptotic factors such as Bax/Bcl-2 and caspases, and the enhancement of reactive oxygen species (ROS) levels. Emodin can activate the apoptosis of cancer cells by activating intrinsic pathways via increasing the expression of cytochrome C, caspase-9, and caspase-3, and via changing the mitochondrial membrane potential; and by extrinsic pathway via increasing the expression of death receptor, caspase-8, and Bak protein.

Emodin has been demonstrated to act as a Janus-activated kinase 2 (JAK2) inhibitor with cytotoxic activities against multiple myeloma in humans. It selectively inhibits the interleukin-6-induced JAK2/STAT3 pathway and induces apoptosis in myeloma cells via the downregulation of myeloid cell leukemia 1 (Mcl-1) cells.

Protein Tyrosine Kinase Inhibition

Emodin exhibits anticancer activity via inhibition of protein tyrosine kinases and is recognized as a protein tyrosine kinase inhibitor active against various tumor cells, including lung, breast, liver, and ovarian cancer cells.

Metabolic Signaling

Emodin mainly regulates AMPK, PPAR, and inflammation-related signaling pathways, and has demonstrated therapeutic effects on obesity, hyperlipidemia, non-alcoholic fatty liver disease, diabetes and its complications, and osteoporosis. Emodin is a regulator of AMP-activated protein kinase (AMPK) and peroxisome proliferator-activated receptors (PPARs).

DNA-Interactive Properties

Emodin can be used as a reversible binding agent for DNA. Emodin has been shown to possess genotoxicity and DNA-damaging properties by stabilizing Topoisomerase II–DNA cleavage complexes and inhibiting ATP hydrolysis. These DNA-interactive properties are double-edged: while they underpin some anticancer activity, they also contribute to safety concerns (see Section 9).

Antiviral Mechanisms

Emodin has antiviral activity achieved by blocking the virus–receptor interaction, restraining the M^pro activity, inhibiting the translation of viral proteins, viral maturation, and the release of virus. The open-reading-frame 3a of SARS coronavirus (SARS-CoV) had been demonstrated to form a cation-selective channel that may become expressed in infected cells and is involved in virus release. Drugs that inhibit the ion channel formed by the 3a protein can be expected to inhibit virus release. Emodin can inhibit the 3a ion channel of coronavirus SARS-CoV and HCoV-OC43, as well as virus release from HCoV-OC43, with a K_1/2 value of about 20 μM.

6. Scientific Evidence by Area of Use

6.1 Gastrointestinal and Laxative Effects

The laxative action of emodin-containing plants is among their most historically established properties. Emodin acts as a stimulant laxative via irritation of the intestinal mucosa, stimulating peristalsis. Overdose of anthraquinone laxatives results in intestinal pain and severe diarrhea with consequent electrolyte imbalance and dehydration. Many case reports have shown that chronic use of anthranoid laxatives and weight-loss products may cause melanosis coli (MC), which can increase the risk of colonic neoplasm.

Evidence strength: The laxative mechanism is well-established pharmacologically, but controlled human clinical trials isolating purified emodin specifically (as distinct from whole-plant rhubarb preparations) are limited. Most evidence derives from animal studies and the long historical record of use with rhubarb-based herbal preparations.

6.2 Anti-Inflammatory Effects

Emodin has a wide range of biological activities, including anti-inflammatory, antibacterial, antiulcer, anticancer, and antinociceptive properties. Much of the mechanistic anti-inflammatory evidence has been generated in animal and cell models. In a severe acute pancreatitis (SAP) model, emodin treatment significantly decreased the expression of multiple inflammatory markers and inhibited phosphorylation of JNK and p38 MAPK by inhibiting ER stress transducers IRE1α and its downstream molecules.

In rats with SAP, emodin at 10 mg/kg was found to significantly suppress systemic inflammatory response syndrome by promoting neutrophil apoptosis via the Ca²⁺/calpain-1/caspase-12/caspase-3 signaling pathway, while at 5 mg/kg it mitigated pancreatic and intestinal mucosal injury by down-regulating caspase-1.

Evidence strength: Predominantly preclinical (cell and animal studies). Human clinical trial data specifically for emodin monotherapy in inflammatory conditions are very limited, and additional human clinical trials to confirm efficacy and safety are needed.

6.3 Anticancer Activity

Emodin has shown significant anticancer activities in several tumor cells, both in vivo and in vitro. Emodin downregulates androgen receptors and inhibits the cellular growth of prostate cancer. It inhibits the adhesion of human breast cancer (MDA-MB-231), human cervix epithelioid carcinoma (HeLa), and human hepatocarcinoma (HepG2) tumor cells by suppressing lipid raft coalescence and interfering with integrin clustering and focal adhesion complex (FAC) formation.

In the AOM/DSS mouse model of colitis-associated intestinal tumorigenesis, emodin at 50 mg/kg reduced inflammatory cell recruitment, cytokine and pro-inflammatory enzyme expression in the tumor microenvironment, while promoting CD3+ T lymphocyte recruitment. Emodin decreased the incidence of premalignant lesions at week 3, dysplastic lesions and carcinomas at week 5, and reduced the incidence, size, and invasiveness of carcinomas at week 14.

According to more recent studies, emodin can also reverse resistance to chemotherapy. In tumor-bearing mice, co-treatment with emodin and cisplatin was shown to suppress tumor growth in vivo by increasing cancer cell apoptosis and downregulating MRP1 expression.

Evidence strength: Extensive preclinical (in vitro and animal) evidence. Controlled human clinical trials are absent or very sparse. The translational relevance of cell-culture studies is substantially limited by emodin's poor oral bioavailability, and clinical translation remains constrained by poor oral exposure and pronounced first-pass metabolism, with extensive glucuronidation and transporter-linked disposition shaping systemic availability.

6.4 Metabolic Diseases: Diabetes and Obesity

Beneficial effects of emodin for diabetes and its complications have been widely reported in preclinical models. Emodin has been preliminarily proven to show antidiabetic effects, though the underlying mechanism on pancreatic β-cells still needs to be elucidated. In cell studies, emodin could alleviate cellular morphological changes, suppress IL-1β and LDH release, and promote insulin secretion in high-glucose-induced INS-1 cells.

Emodin mainly regulates AMPK, PPAR, and inflammation-related signaling pathways, and has a good therapeutic effect on obesity, hyperlipidemia, non-alcoholic fatty liver disease, and diabetes and its complications in preclinical models. Emodin was found to halt the transition from simple steatosis to non-alcoholic steatohepatitis by suppressing Erk1/2 and p38 signaling in in vitro experiments.

Evidence strength: Predominantly animal and in vitro studies. Human clinical trial data for emodin monotherapy in metabolic disease are lacking. Although many studies confirm the use of emodin in the treatment of metabolic diseases, its toxicity may be the main reason it is not used as a therapeutic agent in clinical settings. Randomized controlled clinical trials and design-dosing regimens accounting for biological sex differences are needed.

6.5 Antiviral Activity

Current research on emodin's antiviral effects is based on cell and animal models, and the viruses suppressible by emodin include HSV-1, HSV-2, HCMV, HBV, CVB (types 3–5), EBV, influenza A, SARS-CoV, VHSV, EV71, DENV-2, and ZIKV. The specific antiviral mechanisms vary by virus, while the common denominator is the ability to suppress the inflammatory response caused by viral infection, such as decreasing the expression of IL-6, TNF-α and IFN-β.

SARS-CoV spike protein, a type I membrane-bound protein, is essential for viral attachment to the host cell receptor angiotensin-converting enzyme 2 (ACE2). By screening 312 controlled Chinese medicinal herbs, researchers identified that three widely used Chinese medicinal herbs of the family Polygonaceae inhibited the interaction of SARS-CoV S protein and ACE2. Emodin has been shown to inhibit the ion channel of protein 3a, which could play a role in the release of the virus from infected cells.

Studies on emodin against COVID-19 to date are all based on in vitro experiments and there is limited discussion of its mechanisms, so more research is needed to demonstrate the role emodin could play.

Evidence strength: Exclusively preclinical (in vitro and in silico). No published human clinical trials on antiviral efficacy of isolated emodin have been identified. Results are exploratory and hypothesis-generating.

6.6 Antibacterial Activity

Emodin often inhibits the growth of Gram-positive bacteria, particularly Staphylococcus aureus and methicillin-resistant S. aureus (MRSA). These findings are based entirely on in vitro studies.

Evidence strength: In vitro only. No controlled human clinical trial data for antibacterial application of isolated emodin has been identified.

6.7 Cardiovascular Effects

Emodin has cardioprotective activity in atherosclerosis, myocardial ischemia-reperfusion (I/R) injury, myocardial hypertrophy, hypertension, and hyperlipidemia. Multiple studies have confirmed that emodin has a series of protective effects in cardiovascular diseases, such as anti-inflammatory, immunomodulatory, antiviral, antioxidant and oxygen-free radical scavenging, antifibrotic, and bidirectional regulation of intracellular calcium and L-type calcium channels in cardiac muscle.

Emodin targets multiple features of cardiovascular diseases through a series of pathways. Antioxidant, antiviral, and anti-fibrotic effects are similar to conventional therapeutic methods or target protein inhibitors.

Evidence strength: Predominantly animal and mechanistic studies. No randomized controlled clinical trials in humans for cardiovascular indications with isolated emodin have been identified.

6.8 Renal and Anti-Fibrotic Effects

Emodin, an anthraquinone compound from rhubarb, can inhibit fibrosis in tissues and cells. In a unilateral ureteral obstruction (UUO) animal model, oral administration of emodin significantly ameliorated the loss of body weight and increases in serum uric acid, creatinine, and urea nitrogen. Inflammatory cytokines including tumor necrosis factor-α, monocyte chemoattractant protein-1, and interleukin-1β were down-regulated by emodin administration.

Evidence strength: Animal models only. No human clinical data for anti-fibrotic renal applications with isolated emodin have been identified.

6.9 Acute Pancreatitis

Emodin could significantly alleviate sodium taurocholate-induced pancreatic acinar cell injury in vitro and in vivo through decreasing trypsin, amylase, and the release of inflammatory factors (tumor necrosis factor alpha, interleukin-1β, and interleukin-6). Emodin, known for its potent anti-inflammatory properties, holds promise in addressing acute pancreatitis. However, its clinical application is hindered by limitations such as low bioavailability and insufficient target specificity.

Evidence strength: Preclinical (animal models and cell culture). No pivotal human clinical trials for isolated emodin in pancreatitis have been identified; rhubarb-based preparations have been used clinically in China for pancreatitis, but these cannot be attributed to emodin alone.

7. Pharmacokinetics and Bioavailability

Oral Bioavailability

After administration of 20 mg/kg emodin by gavage, it can be rapidly absorbed by the circulatory system with a half-life of 6.44 hours. However, the oral absorption bioavailability is only 2.83–3.2%, and about 56% of emodin is not absorbed and is excreted out of the body through feces. The absorbed components can be rapidly metabolized to hydroxylated and glucuronidated metabolites, which are mainly distributed in the kidney.

After administration, emodin is rapidly metabolized in the intestine by the phase-II metabolism process, forming its glucuronide conjugate, catalyzed by UDP-glucuronosyltransferases, and the parent compound becomes nearly undetectable in vivo.

When rats were given intravenous emodin at 0.4 mg/kg, it was rapidly metabolized and eliminated, with a half-life of 1.82 hours.

Factors Affecting Bioavailability

Co-administration of emodin with piperine has been shown to improve emodin pharmacokinetics, with a 221% increase in area under the curve (AUC), a 258% increase in maximum concentration (C_max), and a 230% decrease in clearance due to inhibition of glucuronidation.

In a Caco-2 cell culture model, glucuronidation metabolism appeared to be one of the main reasons for the very poor oral bioavailability of emodin. Emodin-nicotinamide co-crystals were found to be two times more soluble than emodin in simulated intestinal fluids, thus enhancing the oral bioavailability of emodin.

Oral administration of emodin is characterized by low bioavailability, as emodin is unfavorable for absorption and distribution after oral administration because of poor water solubility. Female mice appeared to metabolize emodin faster than male mice, whether emodin was injected intraperitoneally or orally, suggesting sex-based differences in metabolism.

Metabolic Pathway and Distribution

Glucuronidation metabolism and oxidative conversion into rhein may be the main reasons for the extremely poor oral bioavailability of emodin. Extensive glucuronidation and transporter-linked disposition shape systemic availability and contribute to variability across dosing regimens and experimental models.

8. Dosage Forms and Dosages Reported in Studies

Experimental and Preclinical Dosages

The following dosages appear in published scientific studies and are presented here solely as a factual record of what has been reported in research. No clinically validated human dosing recommendation exists for emodin as an isolated compound.

• In rat models of severe acute pancreatitis, emodin was studied at 10 mg/kg (to suppress systemic inflammatory response) and 5 mg/kg (to mitigate pancreatic and intestinal mucosal injury).
• In the AOM/DSS mouse model of colitis-associated intestinal tumorigenesis, emodin was used at 50 mg/kg.
• In cell studies examining effects on pancreatic β-cell pyroptosis, INS-1 cells were treated with emodin at 5, 10, and 20 μM when exposed to high glucose.
• The results of the United States National Toxicology Program showed that mice taking emodin at 22 mg/kg were associated with tubular injury (increased incidence of tubular pigmentation) and increased incidence of kidney disease.
• In developmental toxicity studies, emodin was administered in feed to timed-mated rats (0, 425, 850, and 1,700 ppm; gestational days 6–20), and mice (0, 600, 2,500 or 6,000 ppm; gestational days 6–17). Ingested dose was 0, 31, 57, and approximately 80–144 mg emodin/kg/day in rats and 0, 94, 391, and 1,005 mg emodin/kg/day in mice.
• At very high doses (1–3 g/kg/day for mice), emodin has been shown to have laxative effects leading to melanosis.

Formulation Research

Researchers have developed novel drug delivery systems using macrophage membrane-coated nanoparticles loaded with emodin, demonstrating sustained-release properties. However, clinical application of emodin remains hindered by limitations such as low bioavailability and insufficient target specificity. Additional formulation approaches under investigation include nanoparticles (lipid nanoparticles, chitosan nanoparticles, metal-organic framework-based nanoparticles) and co-crystal formulations, all aimed at improving solubility and bioavailability.

9. Safety Considerations

Overview of Toxicity Profile

While emodin possesses a wide spectrum of pharmacological properties, it could also lead to hepatotoxicity, kidney toxicity, and reproductive toxicity, particularly at high doses and with long-term use. Emodin has been reported to induce hepatotoxicity, nephrotoxicity, genotoxicity, and reproductive toxicity. The mechanism of emodin's adverse effects is complicated and currently not well understood.

Hepatotoxicity

Emodin shows hepatotoxicity and nephrotoxicity by inducing apoptosis in the caspase-3-dependent pathway and the mitochondrial pathway. GSH metabolism and the fatty acid metabolism pathways are also involved. Emodin can induce hepatic and renal injury via mitochondrial dysfunction, ROS-linked stress responses, and bioactivation pathways that may generate potentially more reactive metabolites (e.g., 5-hydroxyemodin) under specific enzyme-induction contexts.

Long-term or high-dose emodin showed a cytotoxic effect in hepatocytes and inhibited hepatocyte nuclear factor 4α expression, thereby reducing UDP-glucuronosyltransferase 2B7 (UGT2B7) expression and causing hepatotoxicity. Studies have reported that emodin can cause hepatotoxicity in rats by activating CYP3A and consuming GSH.

Nephrotoxicity

At 12 months in NTP animal studies, the severity of nephropathy increased from minimal in the lower exposure groups to mild in females exposed to 1,250 ppm, with the incidence in this group significantly increased compared to the control group. Results of the United States National Toxicology Program showed that mice taking emodin at 22 mg/kg were associated with tubular injury (increased incidence of tubular pigmentation) and increased incidence of kidney disease.

Genotoxicity and Mutagenicity

It has been suggested that emodin may have mutagenic properties given documented reports of genotoxicity and mutagenicity in certain strains of bacteria. Because emodin is a hydroxyanthraquinone structurally similar to 1,8-dihydroxyanthraquinone, is present in herbal laxatives, and was reported to be mutagenic in bacteria, it was considered a potential carcinogen and was selected for in-depth evaluation by the National Toxicology Program (NTP). Using human peripheral blood lymphocytes (HPBLs), researchers found that emodin could induce cell death and DNA damage at concentrations of 150 μg/mL and 200 μg/mL. At 25 μg/mL, emodin induced an ROS increase, suggesting that emodin has cytotoxicity and genotoxicity against HPBLs, and that oxidative stress is involved in its toxic mechanism.

In the NTP studies, male and female F344/N rats and B6C3F1 mice were exposed to emodin (at least 94% pure) in feed for 16 days, 14 weeks, or 2 years. Genetic toxicology studies were conducted in Salmonella typhimurium, cultured Chinese hamster ovary cells, rat and mouse bone marrow cells, and mouse peripheral blood erythrocytes.

Reproductive Toxicity

Emodin has been reported to exert reproductive toxicity. In male reproductive organs/tissues, the toxicity study of emodin indicated that it has testicular toxicity because of the disruption of the expression of testicular genes. In mouse blastocysts, emodin has been shown to impair embryonic development via intrinsic apoptotic signaling processes resulting in embryonic toxicity at doses of 25, 50, and 75 μM. In human male sperm cells, in vitro studies demonstrated a dose-dependent inhibitory effect of emodin on sperm motility; via progesterone signaling pathways, emodin also reduced the ability of sperm to penetrate viscous media.

Emodin can disrupt the expression of testicular genes and inhibit human sperm function. Long-term administration of high doses of anthraquinone extracts should be avoided altogether during pregnancy. Anthranoid metabolites may be excreted in breast milk.

Laxative Overuse

Chronic use of anthranoid laxatives and weight-loss products may cause melanosis coli (MC), which can increase the risk of colonic neoplasm. Concentration- and time-dependent toxicity of emodin has been observed in liver and kidney cell lines. Overdose of anthraquinone laxatives results in intestinal pain and severe diarrhea with consequent electrolyte imbalance and dehydration.

Gastrointestinal Contraindications

As with other laxatives, use in patients with fecal compaction, intestinal obstruction, and undiagnosed abdominal pain is contraindicated.

Drug Interactions

No well-documented drug interactions with emodin have been formally established. However, given that emodin is extensively metabolized via glucuronidation, co-administration with compounds that inhibit UDP-glucuronosyltransferases could meaningfully alter its systemic exposure. Co-administration with piperine, for example, resulted in a 221% increase in AUC and 258% increase in C_max — illustrating the potential for pharmacokinetic interactions with other phytochemicals.

Bidirectional (Paradoxical) Toxicity and Hepatoprotection

While the number of negative reports is arguably balanced by the number of studies reporting no side effects, uncertainties remain and have hampered enthusiasm for further development of this promising dietary agent. Some studies in the literature report hepatoprotective effects of rhubarb-derived preparations, while others document hepatotoxicity, illustrating the dose-, duration-, and context-dependent nature of emodin's effects on the liver.

10. Current Status and Translational Limitations

Pharmacological research in the last decade has revealed other potential therapeutic applications for emodin, including anticancer, neuroprotective, antidiabetic, antioxidant, and anti-inflammatory effects. Despite the breadth of biological activities documented in preclinical studies, clinical translation remains substantially limited. The application of emodin is greatly limited because of its poor intestinal absorption, rapid elimination, and low bioavailability in vivo after oral administration.

When conducting clinical research on emodin, comprehensive consideration of sex, dosage form, combination with other substances, and glucuronidation of emodin are the main factors to ensure its effectiveness and safety. Formulation strategies including nanoparticle encapsulation, co-crystal formation, and combination with bioavailability-enhancing agents such as piperine are active areas of investigation aimed at bridging the preclinical-to-clinical gap.

References

• Stompor-Gorący M. The Health Benefits of Emodin, a Natural Anthraquinone Derived from Rhubarb—A Summary Update. Int J Mol Sci. 2021;22(17):9522. PMC8431459.
• Semwal RB et al. Emodin: A natural anthraquinone derivative with diverse pharmacological activities. Phytochemistry. 2021;190:112869.
• Dong X et al. Advances in the study of emodin: an update on pharmacological properties and mechanistic basis. Chin Med. 2021;16:102. PMC8504117.
• Ding Y et al. Emodin: A Review of its Pharmacology, Toxicity and Pharmacokinetics. Phytother Res. 2020;34(8):1933–1943. PMC7168079.
• Yu L, Zhao J, Zhao Y. Advances in the pharmacological effects and molecular mechanisms of emodin in the treatment of metabolic diseases. Front Pharmacol. 2023;14:1240820. PMC10644045.
• Guo Y, Zhang R, Li W. Emodin in cardiovascular disease: The role and therapeutic potential. Front Pharmacol. 2022;13:1070567.
• Molecular Mechanisms of Action of Emodin: As an Anti-Cardiovascular Disease Drug. Front Pharmacol. 2020;11:559607.
• The versatile emodin: A natural easily acquired anthraquinone possesses promising anticancer properties against a variety of cancers. Int J Biol Sci. 2022;18(9):3498–3521. PMC9134920.
• Hsu SC, Chung JG. Anticancer potential of emodin. Biomedicine (Taipei). 2012;2(3):108–116. PMC7104001.
• Emodin Inhibits Inflammation, Carcinogenesis, and Cancer Progression in the AOM/DSS Model of Colitis-Associated Intestinal Tumorigenesis. PMC7821392.
• Role of emodin to prevent gastrointestinal cancers: recent trends and future prospective. PMC11972247.
• Shao Y et al. Promising Role of Emodin as Therapeutics to Against Viral Infections. Front Pharmacol. 2022;13:902626. PMC9115582.
• Ho TY et al. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction. Antiviral Res. 2007;74:92–101. PMC7114332.
• Schwarz S et al. Emodin inhibits current through SARS-associated coronavirus 3a protein. Antiviral Res. 2011;90:64–69.
• NMR-based Metabolomic Techniques Identify the Toxicity of Emodin in HepG2 Cells. Sci Rep. 2018. PMC6010407.
• National Toxicology Program. NTP Toxicology and Carcinogenesis Studies of Emodin (CAS No. 518-82-1) Feed Studies in F344/N Rats and B6C3F1 Mice. Natl Toxicol Program Tech Rep Ser. 2001;493:1–278. PMID 12563347.
• Developmental toxicity evaluation of emodin in rats and mice. PubMed PMID 15098202.
• Safety of natural anthraquinone emodin: an assessment in mice. BMC Pharmacol Toxicol. 2021;22:5.
• Emodin and the Anthraquinone Scaffold: Therapeutic Promise and Strategies to Overcome Translational Barriers. Molecules. 2026;31(5):833.
• Emodin Alleviates High-Glucose-Induced Pancreatic β-Cell Pyroptosis by Inhibiting NLRP3/GSDMD Signaling. PMC8898799.
• Emodin Alleviates Sodium Taurocholate-Induced Pancreatic Acinar Cell Injury via MicroRNA-30a-5p-Mediated Inhibition of High-Temperature Requirement A/Transforming Growth Factor Beta 1 Inflammatory Signaling. PMC5681496.
• Emodin improves renal fibrosis in chronic kidney disease by regulating mitochondrial homeostasis through the mediation of PGC-1α. PMC11128849.
• Emodin ameliorates renal injury and fibrosis via regulating the miR-490-3p/HMGA2 axis. Front Pharmacol. 2023;14:1042093. PMC10020706.
• Drugs.com Natural Products Database: Emodin Uses, Benefits & Dosage.
• Wikipedia: Emodin.